Loading...

FITC Annexin V Apoptosis Detection Kit with PI

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5 Apoptosis Detection Kit, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
FITC_Annexin-V_kit_052318
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
  • FITC_Annexin-V_kit_052318
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640914 100 tests 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

BioLegend's FITC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE/Texas Red® channel with a bandpass filter 610/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry.
 

Product Details
Technical Data Sheet (pdf)

Kit Details

Kit Contents
  • 1 vial containing 50 mL of Annexin V Binding Buffer 
  • 1 vial containing 1.0 mL Propidium Iodide Solution 
  • 1 vial containing 0.5 mL Annexin V

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.
Application

FC - Quality tested
Application Notes

Annexin V Staining

  1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend the desired amount of cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 0.25-1.0 x 107 cells/mL
  2. Transfer 100 µL of cell suspension in 5 mL test tube.
  3. Add 5 µL of fluorochrome conjugated Annexin V.
  4. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired.
  5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
  6. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step.
  7. Analyze by flow cytometry.

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Ranhanathan P, et al. 2013. J AM Soc Nephrol. PubMed
  2. Yu J, et al. 2014. PloS One. 9:114650. PubMed
  3. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  4. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
Product Citations
  1. Li H, et al. 2022. Transfusion. 62:663. PubMed
  2. Rashed FB, et al. 2022. Redox Biol. 52:102300. PubMed
  3. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  4. Zaarour RF, et al. 2022. Int J Mol Sci. 23: . PubMed
  5. Khan AN, et al. 2022. Molecules. 27: . PubMed
  6. Wei W, et al. 2022. Mol Med Rep. 26: . PubMed
  7. Li D, et al. 2022. Nucleic Acids Res. 50:12462. PubMed
  8. Park J, et al. 2022. Animals (Basel). 12: . PubMed
  9. Zhang H, et al. 2022. Exp Ther Med. 24:763. PubMed
  10. Bachmann LM, et al. 2023. Molecules. 28: . PubMed
  11. Song X, et al. 2022. Cancer Discov. 12:1294. PubMed
  12. Caballero M, et al. 2022. Front Mol Biosci. 9:752668. PubMed
  13. Lanna A, et al. 2022. Nat Cell Biol. 24:1461. PubMed
  14. Parisay I, et al. 2022. Dent Res J (Isfahan). 19:79. PubMed
  15. Oh C, et al. 2022. Cell Rep. 41:111688. PubMed
  16. Kamalabadi-Farahani M, et al. 2023. Cancer Rep (Hoboken). 6:e1693. PubMed
  17. Tintelnot J, et al. 2023. Nature. 615:168. PubMed
  18. Du Y, et al. 2023. iScience. 26:106114. PubMed
  19. Chen S, et al. 2023. Exp Ther Med. 25:159. PubMed
  20. Tan Z, et al. 2023. Mol Cell Probes. 69:101913. PubMed
  21. Ceniti C, et al. 2023. Foods. 12:. PubMed
  22. Vokshi BH, et al. 2023. Nat Commun. 14:3034. PubMed
  23. Wang L, et al. 2023. Nat Commun. 14:3366. PubMed
  24. Rodina A, et al. 2023. Nat Commun. 14:3742. PubMed
  25. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  26. Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed
  27. Su T, et al. 2021. Metabolites. 11:. PubMed
  28. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  29. Markowicz-Piasecka M, et al. 2020. Apoptosis. 25:426. PubMed
  30. Lyu X, et al. 2019. Oncol Rep. 41:3137. PubMed
  31. Fang H, et al. 2022. Exp Ther Med. 24:440. PubMed
  32. Chen J, et al. 2021. Antioxidants (Basel). 10:. PubMed
  33. Shimonosono M, et al. 2021. Biomolecules. 11:. PubMed
  34. Wang C, et al. 2021. Clin Transl Med. 11:e522. PubMed
  35. Li MM, et al. 2018. Int J Infect Dis. 70:72. PubMed
  36. Guo Q, et al. 2018. Front Immunol. 9:1197. PubMed
  37. Soonthornchai W, et al. 2019. Asian Pac J Allergy Immunol. N/A. PubMed
  38. Kocak P, et al. 2021. Macromol Biosci. 21:e2000287. PubMed
  39. Li D, et al. 2022. Sci Adv. 8:eabm0478. PubMed
  40. Morita K, et al. 2020. Cell. 702:181. PubMed
  41. Yang J, et al. 2021. Oncoimmunology. 1875638:10. PubMed
  42. Xie T, et al. 2021. Ann Transl Med. 9:1249. PubMed
  43. Yuan L, et al. 2015. Endocr Relat Cancer. 22: 577 - 591. PubMed
  44. Belo H, et al. 2015. PLoS One. 10: e0139740. PubMed
  45. Son Y, et al. 2020. Mol Metab. 39:101005. PubMed
  46. Ali DM, et al. 2019. Cell Death Discov. 5:128. PubMed
  47. Yao J, et al. 2018. Onco Targets Ther. 11:3793. PubMed
  48. Choromanska A, et al. 2020. Biomed Rep. 13:32. PubMed
  49. Mahmoud A, et al. 2016. Int J Toxicol. 35: 429 - 437. PubMed
  50. Liu J, et al. 2015. Biochem Biophys Res Commun. 463: Pags 262-267. PubMed
  51. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  52. Neumann CKA, et al. 2020. Mol Metab. 34:136. PubMed
  53. Shao M, et al. 2018. Evid Based Complement Alternat Med. 2018:6049498. PubMed
  54. Coelho CC, et al. 2019. Sci Rep. 9:11050. PubMed
  55. Vashist A, et al. 2022. Asian Pac J Cancer Prev. 23:3629. PubMed
  56. Chang T, et al. 2016. Sci Rep. 6:23403. PubMed
  57. Orgaz JL, et al. 2020. Cancer Cell. 37:85. PubMed
  58. Korencak M, et al. 2019. JCI Insight. 4. PubMed
  59. Zhang W, et al. 2021. J Clin Invest. 131:. PubMed
  60. Kang DY, et al. 2022. J Oncol. 2022:6737248. PubMed
  61. Tatsuno K, et al. 2019. Cell Death Dis. 10:578. PubMed
  62. Ouyang J, et al. 2019. J Surg Res. 233:221. PubMed
  63. Shen L, et al. 2021. Cell Death Discov. 7:392. PubMed
  64. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  65. Saboor-Maleki S, et al. 2016. Technol Cancer Res Treat. 10.1177/1533034616650119. PubMed
  66. Xiao Y, et al. 2020. Nucleic Acids Res. 48:11113. PubMed
  67. Fei X, et al. 2019. Cancer Manag Res. 11:4781. PubMed
  68. Balachandran C, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.06.096. PubMed
  69. Kiss E, et al. 2021. Int J Mol Sci. 22:. PubMed
  70. Wu J, et al. 2020. Immunity. 53:115. PubMed
  71. Sareddy G, et al. 2016. Sci Rep. 6: 24185. PubMed
  72. Xie L, et al. 2020. Front Oncol. 1.354166667. PubMed
  73. Virumbrales–Muñ oz M, et al. 2019. Sci Rep. 9:6199. PubMed
  74. Allur Subramaniyan S, et al. 2018. Cell Commun Adhes. 24:19. PubMed
  75. Chen J, et al. 2021. J Oncol. 2021:5572402. PubMed
  76. Finetti F, et al. 2020. Cell Death Differ. 27:310. PubMed
  77. Xing W, et al. 2020. J Recept Signal Transduct Res. 1:. PubMed
  78. Cao W, et al. 2016. Nat Commun. 7:11687. PubMed
  79. Perez E, et al. 2020. J Immunol. 205:2489. PubMed
  80. Callender LA, et al. 2021. Nat Commun. 12:3379. PubMed
  81. Liu R, et al. 2021. Oncol Lett. 21:06. PubMed
  82. Sohrabi Y, et al. 2019. Front Immunol. 9:3155. PubMed
  83. Changizi V, et al. 2021. Iran J Med Sci. 46:291. PubMed
  84. Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed
  85. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  86. Blue E, et al. 2015. Diabetes. 64: 2664 - 2675. PubMed
  87. Kongkavitoon P, et al. 2016. PLoS One. 11: 0146696. PubMed
  88. Soonthornchai W, et al. 2021. Sci Rep. 11:14186. PubMed
  89. Hu K, et al. 2020. Nat Commun. 2778:11. PubMed
  90. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
  91. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  92. Ryva B, et al. 2019. Front Oncol. 9:100. PubMed
  93. Flegkas A, et al. 2019. Medicines (Basel). 6:1. PubMed
  94. Patil M, et al. 2021. Circ Res. 129:1006. PubMed
  95. Abokyi S, et al. 2021. Int J Mol Sci. 22:. PubMed
  96. Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed
  97. Tailor D, et al. 2020. Br J Cancer. . PubMed
  98. Wu A, et al. 2020. Cell Death Dis. 11:40. PubMed
  99. Huang S, et al. 2022. J Cancer. 13:2662. PubMed
  100. Merikhian P, et al. 2022. Mol Oncol. 16:485. PubMed
  101. Zhou Y, et al. 2021. NPJ Regen Med. 6:34. PubMed
  102. Dudek M, et al. 2021. Nature. 592:444. PubMed
  103. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  104. Wang YL, et al. 2021. Environ Health Perspect. 129:57003. PubMed
  105. Zhou L, et al. 2021. Front Oncol. 11:668617. PubMed
  106. Ma H, et al. 2015. Sci Rep. 5: 15121. PubMed
  107. Kan L, et al. 2015. PLoS One. 10: 0144513. PubMed
  108. Viereckl MJ, et al. 2022. Biomolecules. 12:. PubMed
  109. Roupakia E, et al. 2021. Cancers (Basel). 13:. PubMed
  110. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  111. Zhou Q, et al. 2020. J Invest Dermatol. . PubMed
  112. Chou ST, et al. 2020. Chin Med. 0.678472222. PubMed
  113. Weiss R, et al. 2015. Innate Immunity. 21: 813 - 826. PubMed
  114. Yu J, et al. 2014. PLoS One. 9:114650. PubMed
  115. Yang Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  116. Wang JS, et al. 2021. Nat Commun. 12:6271. PubMed
  117. Li XR, et al. 2020. Neoplasma. 67:982. PubMed
  118. Zakharova I, et al. 2022. Front Bioeng Biotechnol. 10:772981. PubMed
  119. Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed
  120. Cho S, et al. 2019. Transl Oncol. 0.820138889. PubMed
  121. Zamani K, et al. 2021. BMC Biotechnol. 21:68. PubMed
  122. Biadglegne F, et al. 2021. Mol Med Rep. 24:. PubMed
  123. Choromanska A, et al. 2020. Pharmaceutics. 12:00. PubMed
  124. Levy G, et al. 2015. PLoS One. 10: 0136070. PubMed
  125. Li C, et al. 2018. Cell Physiol Biochem. 45:366. PubMed
  126. Wang X, et al. 2020. Onco Targets Ther. 13:1691. PubMed
  127. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  128. Lauko A, et al. 2022. Cell Rep. 40:111348. PubMed
  129. Zhong X, et al. 2021. Oncol Lett. 245:21. PubMed
  130. Wang W, et al. 2020. Cancer Cell Int. 1.06875. PubMed
  131. Lin B, et al. 2020. Mol Med Rep. 21:2171. PubMed
  132. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 7    Revision Date: 05/30/2025

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account